Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Hold rating on Sutro Biopharma (STRO – Research Report). The associated price target is $2.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Andres Y. Maldonado has given his Hold rating due to a combination of factors that reflect both the potential and the challenges facing Sutro Biopharma. The company’s recent updates at AACR 2025 demonstrate promising advancements in their ADC pipeline, particularly with STRO-004 and dual-payload ADCs, which show potential for improved efficacy and reduced toxicity. However, these developments are still in the preclinical stage, and the company is in a transitional phase following the discontinuation of Luvelta.
The Hold rating also considers the broader market pressures and the strategic restructuring Sutro is undergoing, which, while promising, requires time to materialize into tangible results. The valuation, set at a price target of $2, reflects the early development stage of the company and the inherent risks, including regulatory and commercial challenges. Overall, while the scientific fundamentals are strong, patience is required as the company navigates its next steps in development.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Corbus Pharmaceuticals, and Day One Biopharmaceuticals. According to TipRanks, Y. Maldonado has an average return of -7.5% and a 27.27% success rate on recommended stocks.